Recent Company News

• 09:16 AM ET May 08, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:19 AM ET May 08, 2025
  

  StreetAccount Summary - US Pre-market trading

• 07:14 AM ET May 08, 2025
  

  Autolus Therapeutics reports Q1 EPS ($0.26) vs FactSet ($0.24) [7 est, ($0.29)-(0.19)] ($1.23, 0.00)

• 12:09 PM ET Apr 25, 2025
  

  Autolus Therapeutics announces MHRA has granted conditional marketing authorisation for AUCATZYL (obecabtagene autoleucel) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL) ($1.40, 0.00)

• 05:03 PM ET Apr 21, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:16 PM ET Apr 23, 2025
  

  Autolus Therapeutics highlights advancing autoimmune pipeline at R&D Investor Event ($1.51, 0.00)

• 09:03 AM ET Apr 22, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market